Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 5, Issue 1, Pages 9-15
http://dx.doi.org/10.1080/13577140120048890

The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols

1Department of Clinical Pediatrics, UT MD Anderson Cancer Center, Houston, Texas, USA
2The Office of the Chancellor, University of Nebraska Medical Center, Omaha, Nebraska, USA
3The Department of Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA
4Department of Surgery, UT MD Anderson Cancer Center, Houston, Texas, USA
5The Department of Radiation Oncology, Stanford University Medical Center, Stanford, California, USA
6Department of Laboratory Medicine, Columbus Children's Hospital, Columbus, Ohio, USA
7Johns Hopkins Oncology Center, Baltimore, Maryland, USA
8The Department of Pediatric Surgery, Pittsburgh Children's Hospital, Pittsburgh, Pennsylvania, USA
9Office of the Dean, University of Missouri School of Medicine, Columbia, Missouri, USA
10Department of Pediatrics, UT MD Anderson Cancer Center, Box 87, 1515 Holcombe Boulevard, Houston, TX 77030, USA

Copyright © 2001 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

R. Beverly Raney, Harold M. Maurer, James R. Anderson, et al., “The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols,” Sarcoma, vol. 5, no. 1, pp. 9-15, 2001. https://doi.org/10.1080/13577140120048890.